Addie Ketelsen
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Sanofi at 53.0% of the total. 2025 is the largest year on record at $4,059, 6.8 times the $599 reported in 2021. Among family clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $39.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- Johnson & Johnson$1K
- AbbVie$558
- Madrigal Pharmaceuticals$215
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$165
- Takeda Pharmaceuticals U.S.A., Inc.$142
- plus $656 from 9 others
What the payments were for
- Consulting fees$2,35238%
- Travel & lodging$73412%
- Food & beverage$2,91547%
- Education$2564%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 8 | $3,316 |
| Johnson & Johnson | 67 | $1,204 |
| AbbVie | 39 | $558 |
| Madrigal Pharmaceuticals | 2 | $215 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $142 |
| Ironwood Pharmaceuticals, Inc | 8 | $142 |
| Regeneron Healthcare Solutions, Inc. | 2 | $114 |
| Ferring Pharmaceuticals Inc. | 3 | $112 |
| Janssen Scientific Affairs, LLC | 1 | $80 |
| Pfizer | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 1 | $58 |
| Bristol Myers Squibb | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$271
- Rinvoq$123
- RESMETIROM$120
How this compares
$6,256 in reported general payments places this provider in the 95th percentile of 1,121 family providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 179 | $123,812 |
| Dupixent PenDupilumab | 11 | $82,354 |
| XifaxanRifaximin | 23 | $73,219 |
| MotegrityPrucalopride Succinate | 25 | $17,107 |
| TrulancePlecanatide | 12 | $8,709 |
| Balsalazide Disodium | 29 | $6,459 |
| Mesalamine | 26 | $6,158 |
| Pantoprazole Sodium | 555 | $5,214 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,154 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 163 | $3,793 |
| Omeprazole | 419 | $3,598 |
| Ursodiol | 14 | $3,444 |
| Lubiprostone | 14 | $3,294 |
| Famotidine | 382 | $2,882 |
| Mesalamine ErMesalamine | 26 | $2,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $558 | $123,812179 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $165 | $81,92735 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $142 | $17,10725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,121 family providers in Minnesota.
Other family in Anoka
- Erin HewittMinnetonka$172K
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Crista WenischBurnsville$30K
- Kathleen FredellMinneapolis$28K
- Christina RichardsonNorthfield$27K
- Diana CzelMinneapolis$24K
- Alesya ShumkovMinnetonka$22K
- Michelle HigginsStewartville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.